Pyxis Oncology (PYXS) EBT (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly EBT of -$17.0 million for Q4 2025, up 54.94% year-over-year from -$11.0 million in Q4 2024, and up 22.72% quarter-over-quarter from -$22.0 million in Q3 2025.
Pyxis Oncology (PYXS) EBT (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported EBT for 6 consecutive years, with -$17.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, EBT rose 54.94% year-over-year to -$17.0 million; the TTM figure through Dec 2025 stood at -$79.6 million (up 9.48% YoY), while the FY2025 annual figure was -$78.2 million, up 1.59% from the prior year.
- EBT climbed to -$17.0 million in Q4 2025 per PYXS's latest filing, from -$22.0 million in the prior quarter.
- Across five years, EBT topped out at -$5.9 million in Q2 2021 and bottomed at -$46.4 million in Q3 2021.
- Historically, EBT has averaged -$26.6 million across 5 years, with a median of -$23.3 million in 2023.
- Annual changes were most pronounced in 2021 — EBT slumped 1353.15% — and 2025, when it surged 54.94%.
- Pyxis Oncology's EBT stood at -$42.2 million in 2021, then climbed by 15.9% to -$35.5 million in 2022, then jumped by 43.36% to -$20.1 million in 2023, then tumbled by 87.85% to -$37.7 million in 2024, then soared by 54.94% to -$17.0 million in 2025.
- Business Quant data shows PYXS's EBT at -$17.0 million in Q4 2025, -$22.0 million in Q3 2025, and -$18.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Pyxis Oncology | 199.01 Mn | 166.02 Mn | - | -25.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.35 Mn |
| Dec 31, 2025 | -17.00 Mn |
| Sep 30, 2025 | -22.00 Mn |
| Jun 30, 2025 | -18.07 Mn |
| Mar 31, 2025 | -22.56 Mn |
| Dec 31, 2024 | -37.74 Mn |
| Sep 30, 2024 | -21.20 Mn |
| Jun 30, 2024 | -17.30 Mn |
| Mar 31, 2024 | -11.73 Mn |
| Dec 31, 2023 | -20.09 Mn |
| Sep 30, 2023 | -23.99 Mn |
| Jun 30, 2023 | -17.90 Mn |
| Mar 31, 2023 | -25.63 Mn |
| Dec 31, 2022 | -35.46 Mn |
| Sep 30, 2022 | -40.79 Mn |
| Jun 30, 2022 | -39.05 Mn |
| Mar 31, 2022 | -31.82 Mn |
| Dec 31, 2021 | -42.17 Mn |
| Sep 30, 2021 | -46.37 Mn |
| Jun 30, 2021 | -5.94 Mn |